Work

A 4‐Year Follow‐Up of Levodopa‐Entacapone‐Carbidopa Intestinal Gel Treatment in Parkinson's Disease

Year: 2024

Type: article

Abstract: BACKGROUND: Levodopa-entacapone-carbidopa intestinal gel (LECIG) infusion was introduced to the Swedish market in 2019 for Parkinson's disease (PD) with motor fluctuations. Long-term data are lacking. OBJECTIVES: To study long-term data on LECIG treatment. METHODS: A retrospective analysis of the first 24 patients receiving LECIG in Sweden from 2019 to 2023. RESULTS: Five of 24 (21%) patients discontinued LECIG because of side effects, mostly diarrhea. Eight of the 24 (33%) patients died while receiving LECIG. Eleven of 24 (46%) patients were still on LECIG. Median (range) for disease and treatment duration was 19 (9-30) and 3.6 (3.1-4.0) years, respectively, whereas health-related quality of life scales showed median (interquartile range; n) Parkinson's Disease Questionnaire 8-item summary index scores of 38 (4; n = 7), EuroQol 5D scores of 0.59 (0.17; n = 7), and EQ-5D visual analogue scale scores of 65 (10; n = 7). CONCLUSIONS: LECIG infusion is a viable treatment option for PD patients with motor fluctuations, for up to 4 years in our cohort.

Source: Movement Disorders Clinical Practice

DOI: 10.1002/mdc3.14240

Authors: Mezin Öthman, Dag Nyholm

Institution: Uppsala University

Language: English

Topic: Parkinson's Disease Mechanisms and Treatments

Subfield: Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,240